The two most common Canadian government research funding initiatives are IRAP and SR&ED, but how do they differ, and which can best support your business?
The Disruptive Technology Solutions for Cell and Gene Therapy Challenge Program supports the research and development of affordable and accessible therapy solutions for Canadians living with chronic and rare diseases and conditions.
An NRC IRAP investment will help four Canadian businesses to produce safe and effective treatments for those fighting the COVID-19 virus, while also building strong domestic plans to fight future pandemics.
The Government of Canada has extended the Innovation Assistance Program (IAP) by $155 million to continue supporting Canadian businesses through the adverse economic impacts caused by COVID-19.
The NRC has awarded government funding towards Canadian projects that will research and develop solutions to help prevent and fight the COVID-19 pandemic.
With help from NRC-IRAP COVID-19 funding of $299,190, portable coronavirus tests are currently being developed by Canadian biotechnology company Nicoya.
